KEAP1 and multiple sclerosis: Dimethyl fumarate (DMF), an approved drug for multiple sclerosis, can disrupt the KEAP1–Nrf2 interaction by binding to cysteine residues within KEAP1, allowing Nrf2 translocation to the nucleus and Nrf2 transactivation of target genes by binding to their AREs [23].